NCT04137822No Longer AvailableNot Applicable
Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer
Impatients N.V. trading as myTomorrows2 sites in 2 countriesStarted: October 24, 2019Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- No Longer Available
- Sponsor
- Locations
- 2
Study Overview
Brief Summary
An Expanded Access Program for IMM-101 for patients with advanced pancreatic cancer.
Detailed Description
IMM-101 is a suspension of heat-killed whole cell Mycobacterium obuense. Since it is a heat-killed preparation, treatment is not associated with the potential side-effects of delivering live or attenuated organisms.
Five studies with IMM-101 have been completed including a 110-patient randomised Phase II study in pancreatic cancer and exploratory studies in other solid tumours (melanoma, colorectal cancer and advanced melanoma).
Study Design
- Study Type
- Expanded Access
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •This Expanded Access Program is available for patients of 18 years or older with advanced pancreatic cancer for whom, in the opinion of their treating physician, other treatment options or clinical trials in this indication are unsuitable.
Exclusion Criteria
- •Female patient of child-bearing potential who is not, in the opinion of the physician, using an approved method of birth control (e.g., physical barrier [patient and partner], contraceptive pill or patch, spermicide and barrier, or intrauterine device [IUD]).
Investigators
Study Sites (2)
Loading locations...
Similar Trials
No Longer Available
Not Applicable
An Expanded Access Program for AM0010 (Pegilodecakin)Colorectal CarcinomaPancreatic CarcinomaNon-small Cell Lung CarcinomaSolid TumorsBreast CancerProstate CancerOvarian CancerMelanomaRenal Cell CarcinomaNCT03554434Eli Lilly and Company
Completed
Phase 2
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic CancerAdvanced Pancreatic CancerNCT01303172Immodulon Therapeutics Ltd110
No Longer Available
Not Applicable
An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and GliomasGlioma of BrainGlioblastomaNCT03460782Center Trials & Treatment
Approved For Marketing
Not Applicable
Expanded Access for IMMU-132Metastatic Triple-Negative Breast CarcinomaNCT04320693Gilead Sciences
No Longer Available
Not Applicable
Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage TherapeuticNCT03395743Armata Pharmaceuticals, Inc.